Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis

Inclusion Criteria:

- Subjects with chronic, moderate to severe plaque type psoriasis for at least 6 months
prior to randomization and significant involvement of the palms and soles at baseline,
defined as palmoplantar Investigator's Global Assessment (ppIGA) score of ≥ 3 on a
5-point scale, as well as at least one skin plaque at baseline which is not in the
palmoplantar area

- Candidates for systemic therapy, i.e. psoriasis inadequately controlled by topical
treatment (including super potent topical corticosteroids) and/or phototherapy and/or
previous systemic therapy

Exclusion Criteria:

- Forms of psoriasis other than chronic plaque type psoriasis (e.g., pustular psoriasis,
palmoplantar pustulosis, acrodermatitis of Hallopeau, erythrodermic and guttate
psoriasis)

- Drug-induced psoriasis (e.g. new onset or current exacerbation from β-blockers,
calcium channel inhibitors or lithium)

- Ongoing use of prohibited treatments (e.g. topical or systemic corticosteroids (CS),
UV therapy). Washout periods do apply.

- Prior exposure to secukinumab (AIN457) or any other biological drug directly targeting
IL-17 or the IL-17 receptor

- Use of any investigational drugs within 4 weeks prior to study treatment initiation or
within a period of 5 half-lives of the investigational treatment, whichever is longer

- Active ongoing inflammatory diseases other than psoriasis that might confound the
evaluation of the benefit of secukinumab therapy

- History of hypersensitivity to constituents of the study treatment